Search

Researchers from Nanjing Normal University have discovered that the natural product Salidroside enhances the sensitivity of 5-fluorouracil in treating hepatocellular carcinoma (HCC) by inducing mitophagy via the YIPF5 pathway. This combination therapy showed promising results in a mouse model of HCC, suggesting a potential new approach to treating this challenging cancer. The study highlights the importance of drug repurposing and natural product screening in developing innovative cancer treatments. [Extracted from the article]

The article from Cancer Weekly discusses the role of Kinase Suppressor of Ras 2 (KSR2) in promoting self-renewal and clonogenicity of small-cell lung carcinoma (SCLC) cells, particularly in the ASCL1 subtype of SCLC tumors. KSR2 is a molecular scaffold that enhances Raf/MEK/ERK signaling and is expressed in pulmonary neuroendocrine cells, which are identified as cells of origin for SCLC-A tumors. Disruption of KSR2 inhibits the colony-forming ability of tumor-propagating cells in vitro and their tumor-initiating capacity in vivo, suggesting KSR2 as a potential therapeutic target for ASCL1-subtype SCLC tumors. [Extracted from the article]

The article discusses a clinical trial, NCT06762470, focusing on the prognostic value of the circulating lymphocyte CD4/CD8 ratio in patients with non-metastatic nasopharyngeal carcinoma. The study aims to evaluate the significance of this ratio as a prognostic marker before treatment. The trial is being conducted at multiple centers and is actively recruiting participants in China, with a target enrollment of 325 patients. The primary outcome measures include progression-free survival, overall survival, distant metastasis-free survival, and locoregional recurrence-free survival over a three-year period. [Extracted from the article]

A patent application titled "Use Of Gcn2 Inhibitors In Treating Cancer" was published online, detailing a method of treating cancer by administering a GCN2 inhibitor to individuals with low expression or activity of a urea cycle enzyme. The inventors highlight the importance of arginine in cell processes and the potential of GCN2 inhibitors as cancer therapeutics. The application outlines methods for predicting responsiveness to GCN2 inhibitors and inhibiting tumor growth or cell proliferation in various types of cancer, emphasizing the need for targeted treatments based on urea cycle enzyme levels. [Extracted from the article]

A patent application titled "Methods, Compositions, And Systems To Detect Head And Neck Cancer In Saliva Samples" by inventor Gerald J. Wallweber aims to develop improved biomarkers for Head and Neck Squamous Cell Carcinoma (HNSCC). The application focuses on detecting HNSCC in individuals using saliva samples and measuring biomarkers associated with the disease, such as AIM2, CDSN, INHBA, MMP1, MMP9, and MMP10. The goal is to identify individuals at risk for HNSCC, monitor them, and potentially administer treatments. The application highlights the importance of early detection for improving patient survival rates and emphasizes the need for reliable biomarkers in diagnosing and preventing HNSCC. [Extracted from the article]

A recent study conducted by researchers at Nantong University in China focused on the role of POU3F4 in various cancers, exploring its expression patterns, prognostic implications, and functional roles in tumor immunity. The study utilized data from multiple sources to investigate the potential carcinogenic effects of POU3F4, revealing that its expression varies across different cancer types and is associated with prognosis, DNA and RNA methylation, immune cell infiltration, and drug resistance. In vitro experiments showed that POU3F4 enhances cell viability, proliferation, and migration in glioblastoma multiforme (GBM), suggesting its significance as a prognostic marker in diverse malignancies. [Extracted from the article]

A recent study conducted at Baskent University Faculty of Medicine explored the immunohistochemical profile of basosquamous carcinoma (BSC) and its clinicopathological associations. The research analyzed 104 BSC cases diagnosed between 1996 and 2017, revealing high proliferation and ulceration rates. The study highlighted correlations between various immunohistochemical markers and clinicopathological characteristics, shedding light on the potential prognostic significance of these markers for BSC. Long-term follow-up studies are recommended to further clarify these findings. [Extracted from the article]

Researchers at Ditmanson Medical Foundation Chia-Yi Christian Hospital in Taiwan conducted a study on urothelial cancer, focusing on the potential synergistic effects of combining doxorubicin with vorinostat in therapy. The study found that the combination treatment led to decreased cell viability and induced cell death in human bladder cancer cells. The researchers concluded that this combination therapy could be a promising new treatment for urothelial bladder cancer, potentially reducing the side effects of high-dose doxorubicin. [Extracted from the article]

Researchers from Binzhou Medical University in China conducted a study on the effectiveness and safety of combining hepatic arterial infusion chemotherapy (HAIC) with lenvatinib and tislelizumab for advanced hepatocellular carcinoma (HCC) with high tumor burden. The study included 162 treatment-naive patients with advanced HCC, and after propensity score matching, it was found that the group receiving HAIC showed significantly prolonged overall survival and progression-free survival compared to the group without HAIC. The researchers concluded that HAIC combined with lenvatinib and tislelizumab could be a promising treatment option for advanced HCC patients due to improved prognosis and acceptable safety. [Extracted from the article]

A recent study conducted at the Medical University of Plovdiv in Bulgaria focused on analyzing the expression of estrogen receptor alpha (ER alpha) and epidermal growth factor receptor (EGFR) in non-smoking women with lung adenocarcinoma. The research found that there is a correlation between the expression of EGFR mutation and the time of menopause, suggesting a relationship with hormonal and menstrual factors. The study concluded that the expression of ER alpha and EGFR in these women is likely influenced by sex hormones and menstrual factors. [Extracted from the article]

Researchers at Rockefeller University have reported new findings on liver cancer, specifically focusing on Fibrolamellar Hepatocellular Carcinoma (FLC). The study analyzed RNA-seq data from 1412 liver tumors to understand the pathogenesis of FLC and its relationship to other liver tumors. The research identified unique dysregulations in FLC tumors and studied metastases, finding small differences from primary tumors. This study provides valuable insights into the diverse disruptions of protein kinase A in liver cancer. [Extracted from the article]

A recent study conducted by researchers from Capital Medical University in Beijing, China, focused on the survival analysis of patients with hepatocellular carcinoma (HCC) based on the ratio of platelet count to spleen diameter. The study found that the platelet count/spleen diameter ratio (PSL) could predict the presence of esophagogastric varices and portal hypertension, which are risk factors for HCC recurrence. The researchers developed a novel nomogram using LASSO Cox regression, which showed higher predictive efficacy for 3-year overall survival in HCC patients. The study highlights the importance of PSL in predicting the prognosis of HCC patients and could potentially improve patient outcomes. [Extracted from the article]

A recent study conducted at the General Hospital of Ningxia Medical University in China aimed to develop a habitat imaging method for predicting early postoperative recurrence of hepatocellular carcinoma. The study involved a retrospective analysis of 344 patients who underwent liver resection for HCC, utilizing radiomics feature extraction and machine learning classification models. The research concluded that habitat analysis of sequential CT images can delineate distinct subregions within a tumor, providing valuable insights for early prediction of postoperative HCC recurrence. For more information, readers can refer to the article "Prediction of early postoperative recurrence of hepatocellular carcinoma by habitat analysis based on different sequence of contrast-enhanced CT" published in Frontiers in Oncology. [Extracted from the article]

A recent study conducted by researchers at Kurume University School of Medicine focused on the efficacy and safety of chemoradiotherapy (CRT) combined with local consolidative therapy (LCT) for patients with Stage IV non-small cell lung carcinoma (NSCLC) with oligometastases. The study enrolled 19 patients and found that the treatment approach resulted in a 2-year survival rate of 68.4% and a response rate of 58%. The researchers concluded that this combined treatment strategy may extend survival and achieve local control for NSCLC with oligometastases. [Extracted from the article]

Researchers at the National Cancer Institute have developed a tissue factor (TF)-targeted near-infrared photoimmunotherapy (NIR-PIT) as a potential treatment for various types of cancer. The study found that TF expression was present in multiple cancer cell lines both in vitro and in vivo, and TF-targeted NIR-PIT led to cell death in a light dose-dependent manner. In animal models, TF-targeted NIR-PIT suppressed tumor growth and improved survival rates, showing promise as a treatment for different cancer types expressing TF. The research was published in Cancer Immunology, Immunotherapy and was supported by the National Institutes of Health and the National Cancer Institute. [Extracted from the article]

A recent study from Banasthali Vidyapith explores the role of circular RNAs (circRNAs) in colorectal, gastric, liver, and lung cancers. The research highlights the potential of circRNAs as cancer biomarkers and drug targets, with 577 circRNAs identified across these cancer types. The study delves into how circRNAs modulate gene expression in cancer and discusses the challenges and prospects of using circRNAs for cancer diagnostics and therapies. This comprehensive analysis aims to advance cancer research and develop innovative therapies and diagnostics. [Extracted from the article]

A recent study from Sichuan University explored the relationship between microbiota dysbiosis and early-stage lung cancer. The research found differences in microbial composition and metabolic status between early-stage lung adenocarcinoma and squamous carcinoma. Specific flora such as Ralstonia, Feacalibacterium, and Blautia were identified as playing roles in tumor development and progression. This study sheds light on the carcinogenesis of early-stage lung cancer and provides new insights into potential mechanisms. [Extracted from the article]

Researchers at Zhejiang University School of Medicine conducted a study on clear cell renal cell carcinoma (ccRCC) to investigate the cellular and regional heterogeneity of the disease. They identified a novel cancer-promoting subset of regulatory T (Treg) cells that have stronger immunosuppressive function and are associated with a worse prognosis in ccRCC patients. The study also revealed interactions between these Treg cells and tumor-associated macrophages, providing new insights into potential therapeutic targets for ccRCC. The research was published in the Journal for ImmunoTherapy of Cancer and can be accessed for free online. [Extracted from the article]

Researchers at Damietta University have developed a new thiazole derivative with potential anticancer properties and as a topoisomerase II inhibitor. The compound showed strong cytotoxic effects on human cancer cell lines, particularly HepG-2 and MCF-7, while binding strongly to CT-DNA through intercalative mode. Molecular docking studies supported the compound's DNA binding affinity, suggesting a promising avenue for cancer therapy innovation. The study was published in Scientific Reports and can be accessed for further information. [Extracted from the article]

A recent study conducted at the Pravara Institute of Medical Sciences focused on the impact of the Active Cycle of Breathing Technique (ACBT) and Incentive Spirometry on a patient with pleural effusion caused by malignant lung carcinoma. The study found that these interventions significantly improved chest expansion, dyspnoea, and SPO2 levels in the patient. The research highlights the potential benefits of ACBT and Incentive Spirometry in enhancing the quality of life for lung carcinoma patients. [Extracted from the article]

A recent study conducted by researchers at Guangxi Medical University in China explored the impact of Clonorchis sinensis (C. sinensis) infection on hepatocellular carcinoma (HCC) patients. The study found that C. sinensis infection was associated with younger age at cancer onset, male predominance, advanced cancer stage, liver cirrhosis, and microvascular invasion in HCC patients. Additionally, the infection correlated with shorter overall survival and recurrence-free survival, as well as altered levels of blood lipids. The research suggests that C. sinensis triggers inflammation, insulin resistance, and pro-tumor immune escape, providing insights into potential therapeutic targets for HCC patients co-infected with C. sinensis. [Extracted from the article]

A recent report from Inonu University in Malatya, Turkey, discusses the use of procalcitonin (PCT) and Ki-67 expression levels in predicting the biological behavior of hepatocellular carcinoma (HCC) after liver transplantation. The study analyzed 86 HCC patients who underwent liver transplantation and found that Ki-67 levels exceeding 5% significantly affected disease-free survival and overall survival. The research suggests that Ki-67 can be used as a predictive biomarker for HCC, and further studies on standardized PCT antibody staining are needed to determine its potential as a biomarker. [Extracted from the article]

A recent study conducted by Centro Nacional de Investigaciones Oncologicas (CNIO) in Madrid, Spain, explores the potential benefits of cold exposure in treating liver cancer. The research suggests that chronic cold exposure can prolong lifespan in mice with hepatocellular carcinoma (HCC), enhance liver health, and suppress the development of aggressive HCC by reinstating NAD+ levels. These findings highlight the role of cold therapy in attenuating HCC development and potentially other malignancies involving NAD+ modulation. For more information, readers can access the full article in Cell Stress. [Extracted from the article]

A recent study conducted by researchers at Chonnam National University in Gwangju, South Korea, focused on the use of radiofrequency ablation (RFA) as a treatment for hepatocellular carcinoma (HCC). The study analyzed data from 636 patients with HCC who underwent RFA treatment between 2008 and 2017, revealing that the albumin-bilirubin (ALBI) grade was a significant predictor of tumor recurrence and prognosis. The researchers concluded that the ALBI grade could help clinicians identify high-risk patients and improve treatment strategies for individuals with HCC. [Extracted from the article]

A recent study conducted at the First Affiliated Hospital of Soochow University in China explored the impact of a nursing model based on the Transtheoretical model on male patients with primary liver cancer. The study found that patients who received the intervention showed improved self-management abilities, reduced negative emotions, and better quality of life compared to those who received standard treatment. The research suggests that the behavioral stage change theory collaborative nursing model could be beneficial for male patients undergoing primary hepatocellular carcinoma resection. [Extracted from the article]

A recent study conducted by researchers at the University of Tsukuba in Japan focused on enhancing the therapeutic efficacy of sorafenib, a drug used in the treatment of non-small-cell lung cancer. The study developed silica-containing antioxidant nanoparticles to improve drug stability and reduce adverse effects associated with sorafenib. Results showed that the nanoparticles effectively suppressed tumor growth and improved survival rates in a mouse model of Lewis lung carcinoma, highlighting their potential to enhance treatment outcomes while minimizing side effects. This research offers promise for improving therapeutic outcomes in lung cancer treatment. [Extracted from the article]

Researchers from Aarhus University Hospital in Denmark have conducted a study on squamous cell carcinoma, focusing on the clinical utility of circulating human papillomavirus (HPV) across different types of SCCs. The study found that HPV can be detected in circulating tumor DNA, making it a potential biomarker for HPV-associated cancers. The researchers reviewed 41 studies on cervical, head and neck, and anal SCCs, emphasizing the need for coordinated studies to validate the clinical potential of circulating HPV as a biomarker. The full article can be accessed in Acta Oncologica, with contact information for the researchers provided for further inquiries. [Extracted from the article]

A recent study conducted by researchers at Zhengzhou University in the People's Republic of China introduced the Efficient Enhanced Feature Framework (EFF-Net), a deep neural network architecture designed for grading renal cell carcinoma (RCC) using histopathological image analysis. The study aimed to improve the accuracy, processing efficiency, and memory utilization of RCC grading methods. Evaluation across multiple datasets showed that EFF-Net achieved high levels of accuracy, precision, recall, and F1 score, outperforming existing approaches. The research concluded that EFF-Net's superior accuracy, reduced trainable parameters, and computational requirements make it a promising tool for RCC grading. [Extracted from the article]

The article discusses the distinct immune characteristics of hepatocellular carcinoma (HCC) in cases that are positive for Hepatitis B virus (HBV) compared to those that are HBV-negative. Through single-cell RNA sequencing, researchers found that HBV infection alters the immune cell composition and function within the tumor microenvironment, leading to T cell suppression and exhaustion. The study highlights potential targets for immunotherapeutic interventions in HBV-related HCC. [Extracted from the article]

A patent application by inventor Hashimoto, Hiroshi, filed in June 2024, focuses on an ultrasonic diagnostic device for cancer detection. The device aims to determine the timing when contrast agents are discharged from cancerous tissues, aiding in the diagnosis of liver tumors and hepatocellular carcinoma. By analyzing contrast images and characteristic values, the device can identify major/minor relationships to detect changes in tissue luminance over time, even in cases where differences are difficult to observe. This technology has potential implications for improving cancer diagnostics and screening processes. [Extracted from the article]

Researchers at Guangxi Medical University conducted an integrative multi-omics analysis to identify a novel subtype of Hepatocellular Carcinoma (HCC) with biological and clinical relevance. The study constructed a robust prognostic risk model for HCC patients, revealing high-risk subtypes associated with specific signaling pathways and immune cell interactions. This research may aid in personalized drug therapy for HCC patients, offering insights into prognostic risk assessment and treatment strategies. [Extracted from the article]

A recent study conducted at the University of the Punjab in Lahore, Pakistan, explores the role of coagulation factors in hepatocellular carcinoma (HCC), a prevalent form of liver cancer with significant impacts on morbidity and mortality rates. The research highlights the diagnostic, prognostic, and therapeutic significance of essential coagulation biomarkers in HCC, such as P-selectin, thrombomodulin, d-dimer, prothrombin, and von Willebrand factor. The study aims to improve clinical management strategies for patients affected by HCC by elucidating the complex interactions between coagulation abnormalities and the pathophysiological mechanisms underlying the disease. [Extracted from the article]

The article from Cancer Weekly presents research from Xinjiang Medical University on liver cancer, specifically hepatocellular carcinoma (HCC), which accounts for 75%-85% of liver cancer cases globally. The study highlights the need for improved early detection of HCC and the development of assays targeting specific pathways involved in its progression. The research aims to summarize existing markers and explore new ones to provide a basis for future studies. For more information, readers can access the full article in Liver Research. [Extracted from the article]

A recent study conducted at Tehran University of Medical Sciences focused on the dysregulation of microRNAs in oral squamous cell carcinoma (OSCC) and its impact on tumor progression. The research identified key microRNAs and target genes through regulatory network analysis, highlighting potential biomarkers for prognosis and predicting OSCC progression. Financial support for the study was provided by the School of Advanced Technologies in Medicine of Shahid Beheshti University of Medical Sciences. The findings were published in Molecular Biology and can be accessed for further information. [Extracted from the article]

Researchers from Guangzhou Medical University in Guangdong, China, conducted a study on the role of miR-342 and FOXP1 in hepatocellular carcinoma cells. They found that miR-342 can inhibit the FOXP1/MYCBP signaling axis, leading to the inhibition of cell proliferation and promotion of apoptosis in liver cancer cells. This research was supported by the Science and Technology Program of Guangzhou, China, and has been peer-reviewed. For more information, readers can refer to the article "Microrna-342 Inhibits Hepatocellular Carcinoma Cell Proliferation and Promotes Apoptosis Through the Foxp1/mycbp Signaling Axis" published in Toxicology Research in 2024. [Extracted from the article]

Researchers from Westlake University in China conducted a study on liver cancer, focusing on the role of growth differentiation factor 7 (GDF7) in regulating the proliferation and metastasis of hepatocellular carcinoma (HCC). The study found that low levels of GDF7 were associated with worse overall survival and increased recurrence risk in HCC patients. GDF7 was identified as a potential biomarker for predicting better outcomes and a potential therapeutic target for HCC. The research highlights the importance of inflammatory factors and GDFs in the development and progression of liver cancer. [Extracted from the article]

Researchers at Hue University in Vietnam recently reported new findings on small cell lung cancer (SCLC), a type of primary lung cancer that accounts for approximately 15% of cases and is closely linked to tobacco use. The study highlighted the high mortality rate of SCLC due to its rapid growth and early metastasis to sites such as the brain, bones, adrenal glands, liver, lymph nodes, and, rarely, the stomach. The research aims to raise awareness among clinicians about atypical symptoms of gastric metastasis from SCLC to improve patient prognosis. The study has been peer-reviewed and published in the World Journal of Gastroenterology. [Extracted from the article]

Researchers from National Chung Hsing University conducted a study on liver cancer, focusing on the potential of lactoferrin in treating hepatocellular carcinoma (HCC). The study found that lactoferrin exhibited anti-proliferative effects on HCC cells, inducing apoptosis and cell cycle arrest. The research identified Intelectin-1 (INTL1) as the receptor facilitating lactoferrin's action in HCC cells, offering insights for future liver cancer therapy. This study highlights lactoferrin's potential in preventing HCC development and provides valuable mechanistic insights for further exploration in liver cancer treatment. [Extracted from the article]

Researchers from Chiba University conducted a study on liver cancer patients who underwent hepatectomy for hepatocellular carcinoma (HCC). The study found that a low functional liver imaging score (FLIS) was associated with a poor prognosis following surgery. Patients with an FLIS of 6 had better recurrence-free and overall survival rates compared to those with an FLIS of 2-5. The research suggests that surgical decisions should be carefully considered for patients with a low FLIS to improve outcomes. [Extracted from the article]

Researchers at Soran University have published a study on a new personalized medicine approach targeting colorectal carcinoma cells. The study focused on evaluating a drug delivery system encapsulating an mTOR inhibitor on CRC cells with differing P53 statuses. The findings suggest that the PLGA-HA-based drug delivery system shows promising anti-cancer activity, particularly in tumors with functional P53, indicating potential for personalized cancer therapy. The research was conducted by Dlshad H. Hassan, Goran Othman, and Esmaeil Babaei from the Department of Biology at Soran University in Iraq. [Extracted from the article]

Researchers at the University of Catanzaro Magna Graecia discussed a case report on epithelial myoepithelial carcinoma, a rare low-grade malignant tumor of the salivary glands. The report highlighted a case of an 83-year-old man who experienced lymph node metastasis 9 years after an initial diagnosis of EMC in the parotid gland. The researchers emphasized the need for long-term follow-up for EMC cases, as treatment and follow-up guidelines are not well-established due to the rarity of the condition. [Extracted from the article]

Researchers at the University of California San Francisco conducted a study on head and neck squamous cell carcinoma patients in Tanzania, focusing on treatment initiation and completion rates. The study found that a significant number of patients did not initiate or complete treatment, highlighting challenges in resource-constrained health systems. The research emphasized the importance of understanding these metrics to improve care outcomes and develop interventions for head and neck cancer patients in similar settings. [Extracted from the article]

A recent study conducted by researchers at Capital Medical University in Beijing, China, focused on the efficacy of re-resection in recurrent hepatocellular carcinoma (rHCC) and identified prognostic factors for clinical guidance. The study compared disease-free survival (DFS) and overall survival (OS) between rHCC patients undergoing re-resection and primary HCC patients undergoing initial hepatectomy. The research concluded that re-resection is an effective treatment option for rHCC, with favorable outcomes in terms of DFS and OS, although OS was lower compared to initial hepatectomy. Key prognostic factors identified included Child-Pugh classification, time to recurrence, tumor differentiation, and satellite nodules. [Extracted from the article]

Researchers from Mudanjiang Normal University conducted a study on the effectiveness and mechanism of Resibufogenin on human renal cancer cells. The study found that Resibufogenin inhibited renal cancer cells through specific signaling pathways and had strong associative activities with certain genes. The results suggest that Resibufogenin could be a potential treatment for renal cell carcinoma and may contribute to the development of novel drugs in the future. The study was supported by various research foundations and was published in the journal Biology. [Extracted from the article]

A recent study from Weill Cornell Medicine in New York City explores the opposing regulation of the STING pathway in hepatic stellate cells by NBR1 and p62, which impacts the progression of hepatocellular carcinoma (HCC). The research highlights the role of p62 in activating the interferon cascade and its interaction with TRIM32, NBR1, and STING in HSCs. NBR1 emerges as a potential target to enhance anti-tumor responses mediated by CD8+ T cells and restrain HCC progression. This peer-reviewed study provides valuable insights into the molecular mechanisms underlying liver cancer development. [Extracted from the article]

A study conducted by Guizhou Medical University analyzed data from the SEER database to assess the prognostic value of lymph node metrics in lung squamous cell carcinoma (LSCC). The research focused on indicators such as the lymph node ratio (LNR), regional node positivity (RNP), and lymph node examination count (RNE) in predicting cancer-specific survival in LSCC patients. The study found that models incorporating LNR and RNP demonstrated superior performance over the traditional TNM staging system, highlighting their value in predicting long-term survival outcomes for LSCC patients. [Extracted from the article]

Researchers from the Chinese Academy of Sciences conducted a study to re-evaluate the relationship between PrPc expression and patient prognosis in primary esophageal squamous cell carcinoma (ESCC) and primary hepatocellular carcinoma (HCC). Using a novel anti-PrPc antibody, they found that high PrPc expression in ESCC was associated with better overall survival and identified as an independent prognostic factor. In contrast, positive PrPc expression in HCC was linked to shorter recurrence-free survival. This research sheds light on the potential impact of PrPc expression on patient outcomes in these types of cancer. [Extracted from the article]

A study conducted at the Third Affiliated Hospital of Sun Yat-Sen University compared the survival outcomes of patients with stage IA non-small cell lung cancer (2 cm) who underwent sublobectomy, focusing on squamous cell carcinoma (SCC) and adenocarcinoma (ADC) pathology. The research found that patients with SCC had worse overall survival compared to those with ADC. Female sex, high tumor grade, and SCC pathology were identified as independent risk factors for overall survival in these patients. This study provides valuable insights into the prognosis of different types of non-small cell lung cancer following sublobectomy. [Extracted from the article]

Researchers at the University of Delhi have conducted a study on liver cancer therapy using targeted nanotherapy with vinblastine-loaded chitosan-coated PLA nanoparticles. The study focused on the synthesis of biodegradable nanocarriers for drug delivery and evaluated their therapeutic potential in human hepatocellular carcinoma cells. Results showed that the nanoformulation exhibited high anticancer activity due to increased cellular toxicity, cellular uptake, reactive oxygen species production, and disruption in mitochondrial membrane potential. The research suggests potential applications of this nanoformulation in drug delivery systems targeting liver cancer. [Extracted from the article]

Researchers at Kobe University in Hyogo, Japan, conducted a study on the treatment outcomes of hepatectomy and systemic chemotherapy for hepatocellular carcinoma (HCC) based on oncological resectability criteria. The study included 931 patients in the hepatectomy group and 273 in the systemic chemotherapy group, with varying median survival times based on the oncological resectability criteria. The research concluded that the oncological resectability criteria effectively stratified the prognosis after hepatectomy, and patients with two to three BR2-defining factors may benefit from multidisciplinary treatment. [Extracted from the article]